Case Analysis on Real Life Incidence of Photodynamic Therapy (PDT) Safety Outcomes (CALIPSO)

This study has been withdrawn prior to enrollment.
(Sponsor cancelled the study)
Sponsor:
Information provided by (Responsible Party):
Pinnacle Biologics Inc.
ClinicalTrials.gov Identifier:
NCT01203163
First received: September 15, 2010
Last updated: May 7, 2012
Last verified: May 2012
  Purpose

Three main adverse reactions, namely photosensitivity (reaction that is similar to sunburn), oesophageal stenosis (narrowing or closure of the food pipe), perforation of the treated area (a tear or puncture of the tissue), have been identified in research studies evaluating photodynamic therapy (PDT) with porfimer sodium. Because of the low incidence of the disease or the variation in the occurrence of these adverse reactions among different indications, it is difficult to determine the occurrence and frequency of these safety issues in routine clinical practice.

This post-marketing safety surveillance registry is set-up to evaluate the safety of PDT using porfimer sodium. A registry allows the collection of data to evaluate real-world results in the practice of medicine. The registry will monitor the patient's health and any events, with a main focus on photosensitivity, oesophageal stenosis, and perforation of the treated area. This registry will involve 500 patients, across 20 to 36 hospitals in the US and Europe, scheduled to receive an injection of porfimer sodium with PDT for the treatment of lung cancer, esophageal [food pipe] cancer, or high-grade dysplasia (HGD) (precancerous change in the food pipe tissue) in Barrett's esophagus.


Condition
Esophageal Cancer
Lung Cancer
Barrett's Esophagus

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Case Analysis on Real Life Incidence of PDT Safety Outcomes: Multicentre, Observational Post-marketing Safety Surveillance Registry of Patients Exposed to Photodynamic Therapy With Porfimer Sodium: The CALIPSO Registry

Resource links provided by NLM:


Further study details as provided by Pinnacle Biologics Inc.:

Primary Outcome Measures:
  • Proportion of patients experiencing Adverse Reactions of Special Interest [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
    Proportion of patients experiencing photosensitivity reaction, oesophageal stenosis, and/or perforation at the site of laser light application after PDT.


Secondary Outcome Measures:
  • Incidence of the photosensitivity reaction in patients with liver insufficiency (disease) [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
    Possible differences in the incidence of the photosensitivity reaction between patients with and without liver insufficiency

  • Relationships between photosensitivity reaction and skin color [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
  • Overall safety in patients with renal insufficiency (disease) [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]

Enrollment: 0
Groups/Cohorts
PDT with porfimer sodium

Detailed Description:

Patients will be enrolled in the registry upon injection of the porfimer sodium. During normal medical examination, criteria for entry onto the registry will be verified to confirm eligibility, and medical procedures including demographic information, disease history, medical history, physical exam, and clinical laboratory testing performed under normal practice will be collected. Patients will receive PDT as per current practice and will be repeated as per the physician's judgment. All patients will be assessed as per current practice, that is usually at least three times, after a PDT session. Additional visits will be sought for those patients who are presenting photosensitivity reaction, esophageal stenosis, perforation at the site of laser light application, or any unresolved serious adverse reactions at the third visit after treatment. All patients will be requested by their physician to complete a two-part Daily Diary to record adverse reactions using a check-list form and a general section for reporting any adverse events and intake of concomitant medications at the time of the adverse event.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients suffering from esophageal cancer, lung cancer, or HGD in Barrett's esophagus and scheduled to undergo PDT with porfimer sodium

Criteria

Inclusion Criteria:

  • Patients scheduled to undergo PDT with Photofrin
  • Patients must have the mental, literate, and legal ability to give a written informed consent, which must comply with the International Conference on Harmonization (ICH) guidelines and local requirements.

Exclusion Criteria:

  • Patients treated with Photosan®
  • Patients being treated with any investigational drug or participating in any interventional studies, with the exception of investigational photoprotection measures.
  • Patients who are unable or unwilling to complete the follow-up evaluations required for the registry.
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Pinnacle Biologics Inc.
ClinicalTrials.gov Identifier: NCT01203163     History of Changes
Other Study ID Numbers: MA-PO-PHORC07-01
Study First Received: September 15, 2010
Last Updated: May 7, 2012
Health Authority: United States: Food and Drug Administration
Europe: European Medicinal Agency (EMA)

Keywords provided by Pinnacle Biologics Inc.:
PDT
porfimer sodium
esophageal cancer
NSCLC
HGD in BE

Additional relevant MeSH terms:
Barrett Esophagus
Esophageal Neoplasms
Lung Neoplasms
Digestive System Abnormalities
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Head and Neck Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Lung Diseases
Respiratory Tract Diseases
Trioxsalen
Dihematoporphyrin Ether
Photosensitizing Agents
Radiation-Sensitizing Agents
Physiological Effects of Drugs
Pharmacologic Actions
Dermatologic Agents
Therapeutic Uses
Antineoplastic Agents

ClinicalTrials.gov processed this record on April 17, 2014